Statement 27 April 2023

Open letter to G20 Ministers in support of the advancement of the G20 Health Agenda


On 27 April 2023, IFPMA and OPPI issued an open letter to Health Ministers of the G20, highlighting the innovative pharmaceutical industry support for G20 health priorities. 

As a global community, we continue to move through a period of great uncertainty, exacerbated by the impact of the pandemic, which continues to place immense pressure on economies and health systems everywhere. In this context, and with just over six years remaining until the 2030 deadline for the SDGs, important forums such as the G20 play a central role.

We are committed to working collaboratively with the G20 on the priorities identified by the G20 Health Working Group: Health emergencies prevention, preparedness, and response (PPR) with a focus on One Health and antimicrobial resistance; Strengthening cooperation with the pharmaceutical sector with a focus on access and availability to safe, effective, quality vaccines, therapeutics, and diagnostics; and digital health innovation to aid universal health coverage (UHC) and improve service delivery. The innovative pharmaceutical sector has expertise and critical insights across these three priorities.




The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit

Learn more

Media Contact

Elliot Dunster